Pfizer Inc. has announced that the European Commission (EC) has issued a decision amending the marketing authorization for ...

Decoy Therapeutics Inc. has announced that a series of antiviral drug candidates previously designed by its Imp3act platform ...

The respiratory syncytial virus (RSV) infects cells along the human respiratory tract, from the nose to the lungs. Each year ...

A single dose of the recombinant respiratory syncytial virus (RSV) vaccine demonstrates ... funded in part by the US Department of Health and Human Services Biomedical Advanced Research and ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...

The Triad's three main healthcare systems separately announced Wednesday they will lift at 7 a.m. Thursday their respiratory ...

While the ‘official’ flu season may still be a month or two away, reports indicate a rise in respiratory illnesses like the ...

Pfizer’s RSV vaccine Abrysvo receives European approval to help protect adults aged 18-59 against RSV lower respiratory tract disease: New York Wednesday, April 2, 2025, 09:00 H ...

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods ...